<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03918590</url>
  </required_header>
  <id_info>
    <org_study_id>16.15</org_study_id>
    <nct_id>NCT03918590</nct_id>
  </id_info>
  <brief_title>Post Intravitreal Injection Topical NSAID vs. Patching</brief_title>
  <official_title>Pain Control Following Intravitreal Injection Using Topical Nepefanac 0.3% or Pressure Patching: A Prospective, Randomized, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The New York Eye &amp; Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The New York Eye &amp; Ear Infirmary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective randomized trial, to evaluate post-injection comfort measures comparing topical
      NSAID (nepafenac 0.3% suspension) and patching.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single masked, randomized, placebo-controlled study that will enroll approximately
      60 subjects with recent active retina related disease requiring intravitreal agents. Subjects
      will be randomized into one of 3 groups in a 1:1:1 ratio, and assigned to receive nepafenac
      0.3% suspension or a sham procedure. Subjects will have a one in three (33%) chance of
      receiving active treatment (no sham procedure), a one in three (33%) chance of receiving
      patching procedure (no active treatment) or a one in three (33%) chance of receiving placebo
      (no active treatment).

      Study participants will then complete the Visual Analog Scale immediately following injection
      and then after 1 hour, and, 24 hours. The VAS data along with relevant data related to each
      subject's injection will also be compiled, including, but not limited to: drug injected,
      diagnosis, co-morbid conditions, history of previous injections, visual acuity, age, and
      gender.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 3, 2018</start_date>
  <completion_date type="Anticipated">June 3, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group 1: Placebo (Preservative free artificial tears) Group 2: Nepefanac 0.3% suspension Group 3: Patch for 2 hours</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post Intravitreal Injection Measurement of Pain</measure>
    <time_frame>6 hours and 24 hours after intravitreal injection</time_frame>
    <description>Change from Baseline post intravitreal injection pain at 6 and 24 hours as measured by the Numeric Pain Rating Scale. The pain numeric rating scale (NRS), on which patients rate their current pain intensity from 0 (&quot;no pain&quot;) to 10 (&quot;worst possible pain&quot;), at the screening, 6 hours and 24 hours.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <condition>Diabetic Macular Edema</condition>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>A single drop of nepafenac 0.3% suspension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single drop of nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patching</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A light pressure patch applied for two hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A single drop of preservative-free Artificial Tears</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single drop of preservative-free Theratears tear drop, (Akron, Ann Arbor, MI).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)</intervention_name>
    <description>NSAID</description>
    <arm_group_label>A single drop of nepafenac 0.3% suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theratears tear drop, (Akron, Ann 111 Arbor, MI)</intervention_name>
    <description>preservative-free Artificial Tears</description>
    <arm_group_label>A single drop of preservative-free Artificial Tears</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>patching</intervention_name>
    <description>no drug/ patching</description>
    <arm_group_label>Patching</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Already scheduled for anti-VEGF injection based on standard of care for disease
             process.

          -  Ability to provide written informed consent

          -  Capable of complying with study protocol.

          -  Volunteer written informed consent with the understanding that consent may be
             withdrawn by the subject at any time without prejudice to future care

        Exclusion Criteria:

          -  History of past intraocular injection of steroid medication.

          -  Experiencing baseline eye pain

          -  Monocular; non-study eye with VA&lt;20/100.

          -  Unwilling or unable to follow or comply with all study related procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>New York Eye and Ear Infirmary</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 4, 2019</study_first_submitted>
  <study_first_submitted_qc>April 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2019</study_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The New York Eye &amp; Ear Infirmary</investigator_affiliation>
    <investigator_full_name>Ronald Gentile, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nepafenac</mesh_term>
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>May 19, 2019</submitted>
    <returned>June 11, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

